Received Apr 24, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | 5225Y | — |
Administration after temperature excursion; This non-serious case was reported by a other health professional via call center representative and described the occurrence of incorrect storage of drug in a 8-year-old female patient who received HAV (Havrix 720) (batch number 5225Y, expiry date 04-JUL-2027) for prophylaxis. On 14-APR-2026, the patient received the 2nd dose of Havrix 720. On 14-APR-2026, an unknown time after receiving Havrix 720, the patient experienced incorrect storage of drug (Verbatim: Administration after temperature excursion). The outcome of the incorrect storage of drug was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 15-APR-2026 A pharmacy technician reported that Havrix was administered to a patient following a temperature excursion that occurred on the same day. This case is one of the three cases reported.; Sender's Comments: US-GSK-US2026052179:Same reporter/Different patient US-GSK-US2026052178:Same reporter/Diffrent patient